PHP
LLY icon

Parkman Healthcare Partners’s Eli Lilly LLY Stock Holding History

Parkman Healthcare Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42M Buy
35,000
+384
+1% +$392K 4.3% 2
2026
Q1 		$31.8M Buy
+34,616
New +$35.1M 3.28% 5
2025
Q4 		– Sell
-10,000
Closed -$7.63M – 106
2025
Q3 		$7.63M Sell
10,000
-23,296
-70% -$17.3M 0.8% 48
2025
Q2 		$26M Sell
33,296
-5,895
-15% -$4.58M 2.98% 7
2025
Q1 		$32.4M Buy
39,191
+11,028
+39% +$9.18M 3.84% 3
2024
Q4 		$21.7M Sell
28,163
-12,221
-30% -$10.1M 2.9% 7
2024
Q3 		$35.8M Buy
40,384
+8,730
+28% +$7.85M 4.57% 3
2024
Q2 		$28.7M Sell
31,654
-463
-1% -$370K 3.84% 4
2024
Q1 		$25M Buy
+32,117
New +$22.9M 3.07% 6
2023
Q2 		– Sell
-27,671
Closed -$9.5M – 101
2023
Q1 		$9.5M Sell
27,671
-6,767
-20% -$2.28M 2.07% 15
2022
Q4 		$12.6M Sell
34,438
-847
-2% -$300K 3.35% 5
2022
Q3 		$11.4M Buy
+35,285
New +$11.2M 3.24% 6

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parkman Healthcare Partners's LLY Position: Q2 2026 in Review

Parkman Healthcare Partners increased its Eli Lilly (LLY) stake by 1.1% in Q2 2026, buying an estimated $392K and bringing the position to 35,000 shares worth $42M. The position accounts for 4.3% of the portfolio, ranked #2.

Parkman Healthcare Partners first reported a position in LLY in Q3 2022 and has held it in 12 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Parkman Healthcare Partners held 35,000 shares of Eli Lilly worth $42M as of Q2 2026.
  • Parkman Healthcare Partners bought 384 Eli Lilly shares in Q2 2026, an estimated $392K.
  • Eli Lilly made up 4.3% of Parkman Healthcare Partners's portfolio in Q2 2026, its #2 holding.
  • Parkman Healthcare Partners first reported a position in Eli Lilly in Q3 2022 and has held it in 12 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.